

**Table 1.0 Oral Phase Retention for Cohort 1
Week 2 through Week 5**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N Enrolled ¹	110	28	12	10	13	8	22	1	16
Week 2									
Evaluated ²	110	28	12	10	13	8	22	1	16
Visit Completed	97.3% (107/110)	100% (28/28)	100% (12/12)	100% (10/10)	100% (13/13)	87.5% (7/8)	95.5% (21/22)	100% (1/1)	93.8% (15/16)
Early	0% (0/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
On Time	96.4% (106/110)	100% (28/28)	100% (12/12)	100% (10/10)	100% (13/13)	87.5% (7/8)	90.9% (20/22)	100% (1/1)	93.8% (15/16)
Late	0.9% (1/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	4.5% (1/22)	0% (0/1)	0% (0/16)
Visit Not Completed	2.7% (3/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	12.5% (1/8)	4.5% (1/22)	0% (0/1)	6.3% (1/16)
Missed Visit ³	2.7% (3/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	12.5% (1/8)	4.5% (1/22)	0% (0/1)	6.3% (1/16)
Terminated Early ⁴	0% (0/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
Week 4									
Evaluated ²	110	28	12	10	13	8	22	1	16
Visit Completed	95.5% (105/110)	92.9% (26/28)	100% (12/12)	80% (8/10)	92.3% (12/13)	100% (8/8)	100% (22/22)	100% (1/1)	100% (16/16)
Early	0% (0/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
On Time	92.7% (102/110)	89.3% (25/28)	100% (12/12)	80% (8/10)	92.3% (12/13)	87.5% (7/8)	95.5% (21/22)	100% (1/1)	100% (16/16)
Late	2.7% (3/110)	3.6% (1/28)	0% (0/12)	0% (0/10)	0% (0/13)	12.5% (1/8)	4.5% (1/22)	0% (0/1)	0% (0/16)
Visit Not Completed	4.5% (5/110)	7.1% (2/28)	0% (0/12)	20% (2/10)	7.7% (1/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
Missed Visit ³	1.8% (2/110)	7.1% (2/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
Terminated Early ⁴	2.7% (3/110)	0% (0/28)	0% (0/12)	20% (2/10)	7.7% (1/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)
Week 5									
Evaluated ²	110	28	12	10	13	8	22	1	16
Visit Completed	90.9% (100/110)	85.7% (24/28)	91.7% (11/12)	80% (8/10)	92.3% (12/13)	87.5% (7/8)	95.5% (21/22)	100% (1/1)	100% (16/16)
Early	0.9% (1/110)	0% (0/28)	0% (0/12)	0% (0/10)	0% (0/13)	0% (0/8)	0% (0/22)	0% (0/1)	6.3% (1/16)
On Time	86.4% (95/110)	82.1% (23/28)	83.3% (10/12)	80% (8/10)	84.6% (11/13)	87.5% (7/8)	90.9% (20/22)	100% (1/1)	93.8% (15/16)
Late	3.6% (4/110)	3.6% (1/28)	8.3% (1/12)	0% (0/10)	7.7% (1/13)	0% (0/8)	4.5% (1/22)	0% (0/1)	0% (0/16)
Visit Not Completed	9.1% (10/110)	14.3% (4/28)	8.3% (1/12)	20% (2/10)	7.7% (1/13)	12.5% (1/8)	4.5% (1/22)	0% (0/1)	0% (0/16)
Missed Visit ³	4.5% (5/110)	7.1% (2/28)	8.3% (1/12)	0% (0/10)	0% (0/13)	12.5% (1/8)	4.5% (1/22)	0% (0/1)	0% (0/16)
Terminated Early ⁴	4.5% (5/110)	7.1% (2/28)	0% (0/12)	20% (2/10)	7.7% (1/13)	0% (0/8)	0% (0/22)	0% (0/1)	0% (0/16)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 3 Injections	79	15	10	6	10	6	15	1	16
Week 5 Injection 1									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
On Time	96.2% (76/79)	93.3% (14/15)	90% (9/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	93.8% (15/16)
Late	2.5% (2/79)	6.7% (1/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 6 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 9 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 13 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
On Time	98.7% (78/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	93.8% (15/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 17 Injection 2									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	1.3% (1/79)	0% (0/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	97.5% (77/79)	100% (15/15)	80% (8/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Late	1.3% (1/79)	0% (0/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 18 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	1.3% (1/79)	0% (0/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	98.7% (78/79)	100% (15/15)	90% (9/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 23 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	1.3% (1/79)	6.7% (1/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	98.7% (78/79)	93.3% (14/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 29 Injection 3									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	2.5% (2/79)	0% (0/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
On Time	94.9% (75/79)	100% (15/15)	90% (9/10)	100% (6/6)	100% (10/10)	66.7% (4/6)	100% (15/15)	100% (1/1)	93.8% (15/16)
Late	2.5% (2/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	33.3% (2/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 30 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	97.5% (77/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	83.3% (5/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	96.2% (76/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	83.3% (5/6)	93.3% (14/15)	100% (1/1)	93.8% (15/16)
Late	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
Visit Not Completed	2.5% (2/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	16.7% (1/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Missed Visit ³	2.5% (2/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	16.7% (1/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 35 Safety									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	98.7% (78/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	98.7% (78/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Missed Visit ³	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 41 Primary Endpoint									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	100% (79/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	98.7% (78/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	100% (15/15)	100% (1/1)	93.8% (15/16)
Late	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
Visit Not Completed	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Week 53 Follow Up									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	98.7% (78/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Early	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	97.5% (77/79)	100% (15/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	93.8% (15/16)
Late	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	6.3% (1/16)
Visit Not Completed	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Missed Visit ³	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 65 Follow Up									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	97.5% (77/79)	93.3% (14/15)	100% (10/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Early	2.5% (2/79)	6.7% (1/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
On Time	94.9% (75/79)	86.7% (13/15)	90% (9/10)	100% (6/6)	100% (10/10)	100% (6/6)	93.3% (14/15)	100% (1/1)	100% (16/16)
Late	0% (0/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	2.5% (2/79)	6.7% (1/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Missed Visit ³	1.3% (1/79)	6.7% (1/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Terminated Early ⁴	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Week 77 Follow Up									
Evaluated ²	79	15	10	6	10	6	15	1	16
Visit Completed	91.1% (72/79)	86.7% (13/15)	90% (9/10)	83.3% (5/6)	100% (10/10)	100% (6/6)	86.7% (13/15)	100% (1/1)	93.8% (15/16)
Early	2.5% (2/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	12.5% (2/16)
On Time	86.1% (68/79)	73.3% (11/15)	90% (9/10)	83.3% (5/6)	100% (10/10)	100% (6/6)	86.7% (13/15)	100% (1/1)	81.3% (13/16)
Late	2.5% (2/79)	13.3% (2/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	0% (0/15)	0% (0/1)	0% (0/16)
Visit Not Completed	8.9% (7/79)	13.3% (2/15)	10% (1/10)	16.7% (1/6)	0% (0/10)	0% (0/6)	13.3% (2/15)	0% (0/1)	6.3% (1/16)
Missed Visit ³	7.6% (6/79)	13.3% (2/15)	10% (1/10)	16.7% (1/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	6.3% (1/16)
Terminated Early ⁴	1.3% (1/79)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/6)	6.7% (1/15)	0% (0/1)	0% (0/16)
Week 89 Extended Follow Up									
Evaluated ²	72	15	10	6	10	4	12	1	14
Visit Completed	69.4% (50/72)	53.3% (8/15)	30% (3/10)	83.3% (5/6)	80% (8/10)	100% (4/4)	75% (9/12)	100% (1/1)	85.7% (12/14)
Early	4.2% (3/72)	6.7% (1/15)	0% (0/10)	0% (0/6)	0% (0/10)	25% (1/4)	0% (0/12)	0% (0/1)	7.1% (1/14)
On Time	65.3% (47/72)	46.7% (7/15)	30% (3/10)	83.3% (5/6)	80% (8/10)	75% (3/4)	75% (9/12)	100% (1/1)	78.6% (11/14)
Late	0% (0/72)	0% (0/15)	0% (0/10)	0% (0/6)	0% (0/10)	0% (0/4)	0% (0/12)	0% (0/1)	0% (0/14)
Visit Not Completed	30.6% (22/72)	46.7% (7/15)	70% (7/10)	16.7% (1/6)	20% (2/10)	0% (0/4)	25% (3/12)	0% (0/1)	14.3% (2/14)
Missed Visit ³	2.8% (2/72)	0% (0/15)	10% (1/10)	0% (0/6)	0% (0/10)	0% (0/4)	0% (0/12)	0% (0/1)	7.1% (1/14)
Terminated Early ⁴	27.8% (20/72)	46.7% (7/15)	60% (6/10)	16.7% (1/6)	20% (2/10)	0% (0/4)	25% (3/12)	0% (0/1)	7.1% (1/14)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.1 Injection Phase Retention for Cohort 1 Participants with 3 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 101 Extended Follow Up									
Evaluated ²	62	12	9	5	8	4	11	1	12
Visit Completed	58.1% (36/62)	41.7% (5/12)	22.2% (2/9)	80% (4/5)	75% (6/8)	100% (4/4)	45.5% (5/11)	100% (1/1)	75% (9/12)
Early	0% (0/62)	0% (0/12)	0% (0/9)	0% (0/5)	0% (0/8)	0% (0/4)	0% (0/11)	0% (0/1)	0% (0/12)
On Time	58.1% (36/62)	41.7% (5/12)	22.2% (2/9)	80% (4/5)	75% (6/8)	100% (4/4)	45.5% (5/11)	100% (1/1)	75% (9/12)
Late	0% (0/62)	0% (0/12)	0% (0/9)	0% (0/5)	0% (0/8)	0% (0/4)	0% (0/11)	0% (0/1)	0% (0/12)
Visit Not Completed	41.9% (26/62)	58.3% (7/12)	77.8% (7/9)	20% (1/5)	25% (2/8)	0% (0/4)	54.5% (6/11)	0% (0/1)	25% (3/12)
Missed Visit ³	9.7% (6/62)	0% (0/12)	11.1% (1/9)	0% (0/5)	0% (0/8)	0% (0/4)	27.3% (3/11)	0% (0/1)	16.7% (2/12)
Terminated Early ⁴	32.3% (20/62)	58.3% (7/12)	66.7% (6/9)	20% (1/5)	25% (2/8)	0% (0/4)	27.3% (3/11)	0% (0/1)	8.3% (1/12)
Week 105 Final Visit									
Evaluated ²	44	11	6	3	8	0	11	0	5
Visit Completed	56.8% (25/44)	36.4% (4/11)	16.7% (1/6)	100% (3/3)	75% (6/8)	.% (0/0)	63.6% (7/11)	.% (0/0)	80% (4/5)
Early	0% (0/44)	0% (0/11)	0% (0/6)	0% (0/3)	0% (0/8)	.% (0/0)	0% (0/11)	.% (0/0)	0% (0/5)
On Time	56.8% (25/44)	36.4% (4/11)	16.7% (1/6)	100% (3/3)	75% (6/8)	.% (0/0)	63.6% (7/11)	.% (0/0)	80% (4/5)
Late	0% (0/44)	0% (0/11)	0% (0/6)	0% (0/3)	0% (0/8)	.% (0/0)	0% (0/11)	.% (0/0)	0% (0/5)
Visit Not Completed	43.2% (19/44)	63.6% (7/11)	83.3% (5/6)	0% (0/3)	25% (2/8)	.% (0/0)	36.4% (4/11)	.% (0/0)	20% (1/5)
Missed Visit ³	2.3% (1/44)	0% (0/11)	0% (0/6)	0% (0/3)	0% (0/8)	.% (0/0)	9.1% (1/11)	.% (0/0)	0% (0/5)
Terminated Early ⁴	40.9% (18/44)	63.6% (7/11)	83.3% (5/6)	0% (0/3)	25% (2/8)	.% (0/0)	27.3% (3/11)	.% (0/0)	20% (1/5)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.2 Injection Phase Retention for Cohort 1 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 2 Injections	9	4	0	1	1	0	3	0	0
Week 5 Injection 1									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Late	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 6 Safety									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Late	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 9 Safety									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.2 Injection Phase Retention for Cohort 1 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 13 Safety									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 17 Injection 2									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	77.8% (7/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Late	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 18 Safety									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	88.9% (8/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.2 Injection Phase Retention for Cohort 1 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 23 Safety									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 29 Follow Up									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Missed Visit ³	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 41 Primary Endpoint									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Missed Visit ³	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.2 Injection Phase Retention for Cohort 1 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 53 Follow Up									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	100% (9/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Week 65 Follow Up									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	88.9% (8/9)	100% (4/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	66.7% (2/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	66.7% (6/9)	100% (4/4)	.% (0/0)	100% (1/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Late	22.2% (2/9)	0% (0/4)	.% (0/0)	0% (0/1)	100% (1/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Visit Not Completed	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	11.1% (1/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	33.3% (1/3)	.% (0/0)	.% (0/0)
Week 77 Follow Up									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	88.9% (8/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	88.9% (8/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.2 Injection Phase Retention for Cohort 1 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 89 Extended Follow Up									
Evaluated ²	9	4	0	1	1	0	3	0	0
Visit Completed	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Early	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	11.1% (1/9)	25% (1/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Late	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	88.9% (8/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/9)	0% (0/4)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	88.9% (8/9)	75% (3/4)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Week 93 Final Visit									
Evaluated ²	8	3	0	1	1	0	3	0	0
Visit Completed	0% (0/8)	0% (0/3)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Early	0% (0/8)	0% (0/3)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
On Time	0% (0/8)	0% (0/3)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Late	0% (0/8)	0% (0/3)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (8/8)	100% (3/3)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/8)	0% (0/3)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/3)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (8/8)	100% (3/3)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (3/3)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.3 Injection Phase Retention for Cohort 1 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 1 Injections	11	5	1	1	1	1	2	0	0
Week 5 Injection 1									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	0% (0/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Late	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	100% (1/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 6 Safety									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	0% (0/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Late	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	100% (1/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 9 Safety									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	0% (0/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Late	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	100% (1/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.3 Injection Phase Retention for Cohort 1 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 13 Safety									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	0% (0/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Late	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	100% (1/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 17 Follow Up									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Missed Visit ³	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 29 Follow Up									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	81.8% (9/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Early	18.2% (2/11)	20% (1/5)	100% (1/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	63.6% (7/11)	80% (4/5)	0% (0/1)	100% (1/1)	100% (1/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	18.2% (2/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Missed Visit ³	18.2% (2/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.3 Injection Phase Retention for Cohort 1 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 41 Primary Endpoint									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Early	9.1% (1/11)	0% (0/5)	100% (1/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	81.8% (9/11)	100% (5/5)	0% (0/1)	100% (1/1)	100% (1/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Missed Visit ³	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 53 Follow Up									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	90.9% (10/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	50% (1/2)	.% (0/0)	.% (0/0)
Early	9.1% (1/11)	0% (0/5)	100% (1/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	63.6% (7/11)	100% (5/5)	0% (0/1)	100% (1/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Late	18.2% (2/11)	0% (0/5)	0% (0/1)	0% (0/1)	100% (1/1)	100% (1/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Missed Visit ³	9.1% (1/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	50% (1/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Week 65 Follow Up									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 1.3 Injection Phase Retention for Cohort 1 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 77 Follow Up									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Week 81 Final Visit									
Evaluated ²	11	5	1	1	1	1	2	0	0
Visit Completed	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Early	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
On Time	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Late	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/11)	0% (0/5)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/1)	0% (0/2)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (11/11)	100% (5/5)	100% (1/1)	100% (1/1)	100% (1/1)	100% (1/1)	100% (2/2)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.0 Oral Phase Retention for Cohort 2
Week 2 through Week 5**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N Enrolled ¹	89	14	6	13	10	10	2	16	18
Week 2									
Evaluated ²	89	14	6	13	10	10	2	16	18
Visit Completed	96.6% (86/89)	100% (14/14)	100% (6/6)	100% (13/13)	100% (10/10)	90% (9/10)	100% (2/2)	93.8% (15/16)	94.4% (17/18)
Early	0% (0/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	0% (0/18)
On Time	96.6% (86/89)	100% (14/14)	100% (6/6)	100% (13/13)	100% (10/10)	90% (9/10)	100% (2/2)	93.8% (15/16)	94.4% (17/18)
Late	0% (0/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	0% (0/18)
Visit Not Completed	3.4% (3/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	6.3% (1/16)	5.6% (1/18)
Missed Visit ³	2.2% (2/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	6.3% (1/16)	0% (0/18)
Terminated Early ⁴	1.1% (1/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	5.6% (1/18)
Week 4									
Evaluated ²	89	14	6	13	10	10	2	16	18
Visit Completed	95.5% (85/89)	100% (14/14)	100% (6/6)	100% (13/13)	100% (10/10)	90% (9/10)	100% (2/2)	93.8% (15/16)	88.9% (16/18)
Early	0% (0/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	0% (0/18)
On Time	94.4% (84/89)	100% (14/14)	100% (6/6)	100% (13/13)	100% (10/10)	90% (9/10)	100% (2/2)	93.8% (15/16)	83.3% (15/18)
Late	1.1% (1/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	5.6% (1/18)
Visit Not Completed	4.5% (4/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	6.3% (1/16)	11.1% (2/18)
Missed Visit ³	2.2% (2/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	0% (0/16)	5.6% (1/18)
Terminated Early ⁴	2.2% (2/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	6.3% (1/16)	5.6% (1/18)
Week 5									
Evaluated ²	89	14	6	13	10	10	2	16	18
Visit Completed	92.1% (82/89)	71.4% (10/14)	100% (6/6)	100% (13/13)	100% (10/10)	90% (9/10)	100% (2/2)	93.8% (15/16)	94.4% (17/18)
Early	0% (0/89)	0% (0/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	0% (0/16)	0% (0/18)
On Time	80.9% (72/89)	71.4% (10/14)	83.3% (5/6)	92.3% (12/13)	90% (9/10)	50% (5/10)	100% (2/2)	93.8% (15/16)	77.8% (14/18)
Late	11.2% (10/89)	0% (0/14)	16.7% (1/6)	7.7% (1/13)	10% (1/10)	40% (4/10)	0% (0/2)	0% (0/16)	16.7% (3/18)
Visit Not Completed	7.9% (7/89)	28.6% (4/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	6.3% (1/16)	5.6% (1/18)
Missed Visit ³	2.2% (2/89)	7.1% (1/14)	0% (0/6)	0% (0/13)	0% (0/10)	10% (1/10)	0% (0/2)	0% (0/16)	0% (0/18)
Terminated Early ⁴	5.6% (5/89)	21.4% (3/14)	0% (0/6)	0% (0/13)	0% (0/10)	0% (0/10)	0% (0/2)	6.3% (1/16)	5.6% (1/18)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 5 Injections	71	10	6	12	7	6	2	11	17
Week 5 Injection 1									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	87.3% (62/71)	100% (10/10)	83.3% (5/6)	91.7% (11/12)	85.7% (6/7)	50% (3/6)	100% (2/2)	100% (11/11)	82.4% (14/17)
Late	12.7% (9/71)	0% (0/10)	16.7% (1/6)	8.3% (1/12)	14.3% (1/7)	50% (3/6)	0% (0/2)	0% (0/11)	17.6% (3/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 6 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 9 Injection 2									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	5.9% (1/17)
On Time	94.4% (67/71)	90% (9/10)	83.3% (5/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	94.1% (16/17)
Late	4.2% (3/71)	10% (1/10)	16.7% (1/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 10 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	98.6% (70/71)	100% (10/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 13 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 17 Injection 3									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	93% (66/71)	90% (9/10)	100% (6/6)	91.7% (11/12)	71.4% (5/7)	83.3% (5/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	7% (5/71)	10% (1/10)	0% (0/6)	8.3% (1/12)	28.6% (2/7)	16.7% (1/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 18 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 21 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 25 Injection 4									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	2.8% (2/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	5.9% (1/17)
On Time	87.3% (62/71)	90% (9/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	0% (0/6)	100% (2/2)	100% (11/11)	94.1% (16/17)
Late	9.9% (7/71)	10% (1/10)	0% (0/6)	0% (0/12)	0% (0/7)	100% (6/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 26 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	87.3% (62/71)	90% (9/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	0% (0/6)	100% (2/2)	100% (11/11)	94.1% (16/17)
Late	11.3% (8/71)	10% (1/10)	0% (0/6)	0% (0/12)	0% (0/7)	100% (6/6)	0% (0/2)	0% (0/11)	5.9% (1/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 29 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	98.6% (70/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	83.3% (5/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	16.7% (1/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 33 Injection 5									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	100% (71/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	90.1% (64/71)	100% (10/10)	100% (6/6)	100% (12/12)	100% (7/7)	0% (0/6)	100% (2/2)	100% (11/11)	94.1% (16/17)
Late	9.9% (7/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	100% (6/6)	0% (0/2)	0% (0/11)	5.9% (1/17)
Visit Not Completed	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 34 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	98.6% (70/71)	100% (10/10)	100% (6/6)	91.7% (11/12)	100% (7/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	9.1% (1/11)	0% (0/17)
On Time	76.1% (54/71)	90% (9/10)	100% (6/6)	91.7% (11/12)	85.7% (6/7)	0% (0/6)	50% (1/2)	81.8% (9/11)	70.6% (12/17)
Late	21.1% (15/71)	10% (1/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	100% (6/6)	50% (1/2)	9.1% (1/11)	29.4% (5/17)
Visit Not Completed	1.4% (1/71)	0% (0/10)	0% (0/6)	8.3% (1/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	1.4% (1/71)	0% (0/10)	0% (0/6)	8.3% (1/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 37 Safety									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	98.6% (70/71)	100% (10/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	97.2% (69/71)	100% (10/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	83.3% (5/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	16.7% (1/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Week 41 Primary Endpoint									
Evaluated ²	71	10	6	12	7	6	2	11	17
Visit Completed	98.6% (70/71)	100% (10/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Early	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
On Time	98.6% (70/71)	100% (10/10)	100% (6/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (17/17)
Late	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Visit Not Completed	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Missed Visit ³	0% (0/71)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)
Terminated Early ⁴	1.4% (1/71)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/17)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 53 Tail									
Evaluated ²	69	10	6	12	7	6	2	11	15
Visit Completed	95.7% (66/69)	100% (10/10)	66.7% (4/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (15/15)
Early	1.4% (1/69)	10% (1/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/15)
On Time	94.2% (65/69)	90% (9/10)	66.7% (4/6)	100% (12/12)	85.7% (6/7)	100% (6/6)	100% (2/2)	100% (11/11)	100% (15/15)
Late	0% (0/69)	0% (0/10)	0% (0/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/15)
Visit Not Completed	4.3% (3/69)	0% (0/10)	33.3% (2/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/15)
Missed Visit ³	2.9% (2/69)	0% (0/10)	33.3% (2/6)	0% (0/12)	0% (0/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/15)
Terminated Early ⁴	1.4% (1/69)	0% (0/10)	0% (0/6)	0% (0/12)	14.3% (1/7)	0% (0/6)	0% (0/2)	0% (0/11)	0% (0/15)
Week 65 Tail									
Evaluated ²	56	8	3	11	6	6	2	8	12
Visit Completed	91.1% (51/56)	100% (8/8)	33.3% (1/3)	90.9% (10/11)	83.3% (5/6)	100% (6/6)	100% (2/2)	100% (8/8)	91.7% (11/12)
Early	0% (0/56)	0% (0/8)	0% (0/3)	0% (0/11)	0% (0/6)	0% (0/6)	0% (0/2)	0% (0/8)	0% (0/12)
On Time	91.1% (51/56)	100% (8/8)	33.3% (1/3)	90.9% (10/11)	83.3% (5/6)	100% (6/6)	100% (2/2)	100% (8/8)	91.7% (11/12)
Late	0% (0/56)	0% (0/8)	0% (0/3)	0% (0/11)	0% (0/6)	0% (0/6)	0% (0/2)	0% (0/8)	0% (0/12)
Visit Not Completed	8.9% (5/56)	0% (0/8)	66.7% (2/3)	9.1% (1/11)	16.7% (1/6)	0% (0/6)	0% (0/2)	0% (0/8)	8.3% (1/12)
Missed Visit ³	7.1% (4/56)	0% (0/8)	66.7% (2/3)	9.1% (1/11)	0% (0/6)	0% (0/6)	0% (0/2)	0% (0/8)	8.3% (1/12)
Terminated Early ⁴	1.8% (1/56)	0% (0/8)	0% (0/3)	0% (0/11)	16.7% (1/6)	0% (0/6)	0% (0/2)	0% (0/8)	0% (0/12)
Week 77 Tail									
Evaluated ²	19	2	2	1	4	4	0	0	6
Visit Completed	89.5% (17/19)	100% (2/2)	100% (2/2)	100% (1/1)	75% (3/4)	100% (4/4)	.% (0/0)	.% (0/0)	83.3% (5/6)
Early	0% (0/19)	0% (0/2)	0% (0/2)	0% (0/1)	0% (0/4)	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/6)
On Time	89.5% (17/19)	100% (2/2)	100% (2/2)	100% (1/1)	75% (3/4)	100% (4/4)	.% (0/0)	.% (0/0)	83.3% (5/6)
Late	0% (0/19)	0% (0/2)	0% (0/2)	0% (0/1)	0% (0/4)	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/6)
Visit Not Completed	10.5% (2/19)	0% (0/2)	0% (0/2)	0% (0/1)	25% (1/4)	0% (0/4)	.% (0/0)	.% (0/0)	16.7% (1/6)
Missed Visit ³	5.3% (1/19)	0% (0/2)	0% (0/2)	0% (0/1)	0% (0/4)	0% (0/4)	.% (0/0)	.% (0/0)	16.7% (1/6)
Terminated Early ⁴	5.3% (1/19)	0% (0/2)	0% (0/2)	0% (0/1)	25% (1/4)	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/6)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.1 Injection Phase Retention for Cohort 2 Participants with 5 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 89 Extended Followup									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 101 Extended Followup									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 109 Final Visit									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 4 Injections	4	0	0	1	1	1	0	1	0
Week 5 Injection 1									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 6 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	0% (0/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	25% (1/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	100% (1/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 9 Injection 2									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	0% (0/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	25% (1/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	100% (1/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 10 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	0% (0/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	25% (1/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	100% (1/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 13 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 17 Injection 3									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 18 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 21 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 25 Injection 4									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	0% (0/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	25% (1/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	100% (1/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 26 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	0% (0/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	25% (1/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	100% (1/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 29 Safety									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (4/4)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 41 Primary Endpoint									
Evaluated ²	4	0	0	1	1	1	0	1	0
Visit Completed	75% (3/4)	.% (0/0)	.% (0/0)	0% (0/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	75% (3/4)	.% (0/0)	.% (0/0)	0% (0/1)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	25% (1/4)	.% (0/0)	.% (0/0)	100% (1/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	25% (1/4)	.% (0/0)	.% (0/0)	100% (1/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/4)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 53 Tail									
Evaluated ²	3	0	0	0	1	1	0	1	0
Visit Completed	100% (3/3)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (3/3)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 65 Tail									
Evaluated ²	3	0	0	0	1	1	0	1	0
Visit Completed	100% (3/3)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Early	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
On Time	100% (3/3)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	100% (1/1)	.% (0/0)	100% (1/1)	.% (0/0)
Late	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Visit Not Completed	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Missed Visit ³	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Terminated Early ⁴	0% (0/3)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	0% (0/1)	.% (0/0)	0% (0/1)	.% (0/0)
Week 77 Tail									
Evaluated ²	1	0	0	0	0	1	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.2 Injection Phase Retention for Cohort 2 Participants with 4 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 89 Extended Followup									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 101 Final Visit									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.4 Injection Phase Retention for Cohort 2 Participants with 2 Injections
First Injection through End of Study**

There are no Participants in Cohort 2 with only 3 Injections.

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.4 Injection Phase Retention for Cohort 2 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 2 Injections	2	0	0	0	0	2	0	0	0
Week 5 Injection 1									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 6 Safety									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 9 Injection 2									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.4 Injection Phase Retention for Cohort 2 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 10 Safety									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	50% (1/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 13 Safety									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 27 Follow Up									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.4 Injection Phase Retention for Cohort 2 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 41 Primary Endpoint									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 53 Tail									
Evaluated ²	2	0	0	0	0	2	0	0	0
Visit Completed	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (2/2)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/2)	.% (0/0)	.% (0/0)	.% (0/0)
Week 65 Tail									
Evaluated ²	1	0	0	0	0	1	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.4 Injection Phase Retention for Cohort 2 Participants with 2 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 77 Extended Followup									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 85 Final Visit									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.5 Injection Phase Retention for Cohort 2 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
N receiving 1 Injections	1	0	0	0	1	0	0	0	0
Week 5 Injection 1									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 6 Safety									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 9 Follow Up									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.5 Injection Phase Retention for Cohort 2 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 13 Safety									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 27 Follow Up									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 41 Primary Endpoint									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.5 Injection Phase Retention for Cohort 2 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 53 Tail									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 65 Tail									
Evaluated ²	1	0	0	0	1	0	0	0	0
Visit Completed	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	100% (1/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	0% (0/1)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Week 77 Extended Followup									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.

**Table 2.5 Injection Phase Retention for Cohort 2 Participants with 1 Injections
First Injection through End of Study**

	All	UNC AIDS CRS Site ID 257	UCLA CRS Site ID 258	San Francisco Bridge HIV Site ID 259	GWU CRS Site ID 260	Soweto CTU Site ID 261	Vulindlela CRS Site ID 262	Lilongwe UNC Prevention and Treatment Site ID 263	Rio de Janeiro Site ID 264
Week 81 Final Visit									
Evaluated ²	0	0	0	0	0	0	0	0	0
Visit Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Early	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
On Time	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Late	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Visit Not Completed	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Missed Visit ³	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)
Terminated Early ⁴	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)	.% (0/0)

¹ Number of participants enrolled. (Does not include inappropriately enrolled participant).

² Number of participants evaluated at this visit. A participant is evaluated at a given visit if a) the visit window for that participant has closed as of the data evaluation date (20SEP2017), b) the visit window has not closed but the participant completed the visit as of the data evaluation date, or c) the participant has terminated early from the study. For placebo recipients, visits that opened or were completed on or after unblinding (18MAY2017) are not evaluated.

³ A visit is evaluated as missed if the visit window has closed as of the data evaluation date, the participant has not terminated from the study, and no information on visit completion has been received.

⁴ Early termination can occur at any time and is not constrained to scheduled visits. Early terminations are shown cumulatively for all visits affected by early termination.